Characterization of concrete failure behavior: a comprehensive experimental database for the calibration and validation of concrete models

Concrete is undoubtedly the most important and widely used construction material of the late twentieth century. Yet, mathematical models that can accurately capture the particular material behavior under all loading conditions of significance are scarce at best. Although concepts and suitable models have existed for quite a while, their practical significance is low due to the limited attention to calibration and validation requirements and the scarcity of robust, transparent and comprehensive methods to perform such tasks. In addition, issues such as computational cost, difficulties associated with calculating the response of highly nonlinear systems, and, most importantly, lack of comprehensive experimental data sets have hampered progress in this area. This paper attempts to promote the use of advanced concrete models by (a) providing an overview of required tests and data preparation techniques; and (b) making a comprehensive set of concrete test data, cast from the same batch, available for model development, calibration, and validation. Data included in the database ‘http://www.baunat.boku.ac.at/cd-labor/downloads/versuchsdaten’ comprise flexure tests of four sizes, direct tension tests, confined and unconfined compression tests, Brazilian splitting tests of five sizes, and loading and unloading data. For all specimen sets the nominal stress–strain curves and crack patterns are provided.Austria. Ministry of Environment, Youth and FamilyAustria. National Foundation for Research, Technology and DevelopmentUnited States. Dept. of Transportation (Grant No. 20778

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

Multidrug resistance is often associated with the (over)expression of drug efflux transporters of the ATP-binding cassette (ABC) protein family. This minireview discusses the role of one selected ABC-transporter family member, the breast cancer resistance protein (BCRP/ABCG2), in the (pre)clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors